Entera Bio (ENTX) Corrects After The Recent Solid Up Move: What Next?

Among the stocks that recorded considerable losses last week, the Entera Bio Ltd (NASDAQ: ENTX) stock was perhaps one of the more notable ones.

Entera Bio is one of the better-known names among companies that are known for developing large molecule therapies that are delivered orally. Back on March 18, the company announced its financial results for the fourth quarter of 2020 and also for the full year 2020. During the course of the last week, the stock had recorded declines of as deep as 25%.

In addition to that, the company also provided key updates with regards to some of its preclinical programs. The company noted that its human parathyroid hormone product EB613 has got IND approval from the FDA and the enrolment for the Phase 2 trial in Israel has been completed. On the other hand, the revenues for the full year 2020 came in at $365,000, which was substantially higher than the revenues of $235,000 in the year-ago period.

Uson Abdilazhanov

Editor and Computer Expert A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.

Want Hot Stocks?    Yes. I Love Them No thanks